Method for improving capacity of microorganisms for producing glutamine or glutamine derivatives
By reducing the expression level of isocitrate lyase and weakening the glyoxylic acid cycle, the method of replacing the starting codon and inserting terminator is used to significantly improve the glutamine production capacity of microorganisms, and solve the low conversion rate in the prior art The problem of achieving efficient glutamine production.
Patent Information
- Application Number
- CN202310564085.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
AI Technical Summary
The conversion rate of existing microorganisms to produce glutamine during fermentation is not ideal and cannot meet the needs of industrial production.
By reducing the expression level of isocitrate lyase in microorganisms, weakening the glyoxylic acid cycle, weakening the glyoxylic acid synthesis pathway, and replacing the starting codon and insertion terminator to increase the glutamine yield.
It significantly improves the ability of microorganisms to produce glutamine, with a yield increase of up to about 20%, and is suitable for the production of existing glutamine or its derivatives.
Smart Images

Figure BDA0004236147260000031 
Figure BDA0004236147260000041 
Figure BDA0004236147260000061
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene engineering technology, and in particular to a method for improving the ability of microorganisms to produce glutamine or its derivatives. Background Art
[0002] Glutamine is a non-essential amino acid. Its chemical name is 2-amino-4-carbamoylbutyric acid. Glutamine is a coded amino acid in protein synthesis. It can promote protein synthesis and inhibit protein decomposition. It can be used to treat gastric and duodenal ulcers and plays an important role in the pharmaceutical industry.
[0003] At present, the most commonly used production method of glutamine is fermentation, which mainly produces glutamine by fermentation with Corynebacterium glutamicum as the production bacteria. Corynebacterium glutamicum is a heterotrophic aerobic type, a Gram-positive bacterium, with the characteristics of fast growth rate, non-pathogenicity, and weak degradation ability of its own metabolites. The fermentation method has the advantages of wide source of raw materials, low production cost, controllable product quality, and single product. However, the fermentation performance of the strains currently producing glutamine is still poor, and the glutamine conversion rate is still unsatisfactory. However, the demand for glutamine in industry is extremely high, and relying solely on existing strains for fermentation cannot meet the needs of large-scale industrial production. Summary of the invention
[0004] In order to solve the problems existing in the prior art, the present invention provides a method for improving the ability of microorganisms to produce glutamine or its derivatives.
[0005] In a first aspect, the present invention provides a method for improving the ability of a microorganism to produce glutamine or its derivatives, comprising: reducing the expression level of isocitrate lyase in the microorganism.
[0006] The glyoxylate cycle divides a portion of the carbon flow at the isocitrate node, weakening the synthesis of α-ketoglutarate, thereby reducing the accumulation of glutamine. Therefore, the present invention weakens the glyoxylate cycle and weakens the first gene aceA in the glyoxylate synthesis pathway, thereby achieving the purpose of increasing glutamine production.
[0007] Further, the expression level of isocitrate lyase in the microorganism is reduced by reducing the expression level of aceA, a gene encoding isocitrate lyase;
[0008] The method of reducing the expression level of the isocitrate lyase encoding gene aceA includes any one or more of the following methods:
[0009] i) RNA interference technology; ii) replacement of promoter; iii) insertion of terminator; iv) replacement of start codon; v) knockout of large gene fragments; vi) gene mutation.
[0010] Furthermore, the expression level of the isocitrate lyase encoding gene aceA in the microorganism is reduced by replacing the start codon and / or inserting a terminator.
[0011] There are many methods in the prior art to reduce the expression level of the aceA gene encoding isocitrate lyase, but the weakening of the expression of isocitrate lyase is not necessarily better. The experimental results of the present invention show that the recombinant strain obtained by replacing the start codon and inserting the terminator has a higher glutamine production efficiency than that of directly knocking out the aceA gene in a large fragment.
[0012] Furthermore, the above replacement of the start codon is to replace the start codon with TTG; the above insertion of the terminator is to insert the terminator rrnB after the isocitrate lyase coding gene aceA.
[0013] Furthermore, the above isocitrate lyase comprises the amino acid sequence shown in SEQ ID NO.1.
[0014] Furthermore, the gene encoding the isocitrate lyase described above comprises the nucleotide sequence shown in SEQ ID NO.2.
[0015] Furthermore, the above-mentioned glutamine or its derivatives include one or more of glutamine, arginine or tryptophan.
[0016] Furthermore, the above-mentioned microorganisms include one or more of Enterobacter, Bacillus subtilis or Corynebacterium.
[0017] In a second aspect, the present invention provides an aceA mutant, wherein the aceA mutant is encoded by a nucleotide sequence as shown in SEQ ID NO.3 or SEQ ID NO.4.
[0018] When the nucleotide sequence is SEQ ID NO.4, the encoded amino acid sequence is shown as SEQ ID NO.5.
[0019] The present invention further provides the use of the aceA mutant or a biological material comprising the aceA mutant in improving the ability of a microorganism to produce glutamine or its derivatives.
[0020] Furthermore, the biological material includes one or more of an expression cassette, a vector, a transgenic cell or a kit.
[0021] The present invention has the following beneficial effects:
[0022] The present invention has found that modifying isocitrate lyase in microorganisms can regulate their ability to produce glutamine or its derivatives, specifically reducing its expression level, which can significantly improve the ability of microorganisms to produce glutamine or its derivatives. The method provided by the present invention can be applied to the existing production of glutamine or its derivatives, and the expression level of the coding gene of isocitrate lyase can be reduced by replacing the start codon, adding a terminator, knocking out a gene, etc., to achieve an increase in the production level of glutamine or its derivatives, which can reach up to about 20%. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0024] The sequences of the primers involved in the following examples are shown in Table 1 below:
[0025] Table 1 Primer sequences
[0026]
[0027]
[0028] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0029] Example 1
[0030] This example provides a method for constructing multiple recombinant strains modified with the aceA gene, and the specific process is as follows:
[0031] 1. Construction of plasmid pK18-rrnB
[0032] Phusion ultra-fidelity polymerase (New England BioLabs) was used to prepare the recombinant fragment UP1 using the genome of Corynebacterium glutamicum ATCC 14067 as a template and UP1-F / UP1-R as primers. The recombinant fragment rrnB was amplified using plasmid pXMJ19 (commercial plasmid) as a template and rrnB-F / rrnB-R as primers. The recombinant fragment DN1 was prepared using DN1-F / DN1-R as primers. The obtained fragment was purified by an agarose gel recovery kit (Tian Gen). Subsequently, UP1, rrnB, and DN1 were used as templates and UP1-F / DN1-R as primers to prepare the recombinant fragment. The obtained recombinant fragment was purified by an agarose gel recovery kit (Tian Gen) and then digested with XbaI / HindIII. At the same time, pK18-mobsacB (Wuhan Miaoling Biotechnology Co., Ltd.) was digested with XbaI / HindIII and ligated with T4 DNA ligase (TransGen Biotech) to connect the fragment to the vector, transform Trans1T1 competent cells (TransGen Biotech), pick kanamycin-resistant clones, and identify positive clones with fragments inserted into pK18mobsacB by XbaI / HindIII digestion. Further, sequencing with P82 / P85 primers (Invitrogen) was used to identify that the inserted fragment was correct. The resulting plasmid was named pK18-rrnB.
[0033] 2. Construction of strain MHZ-0513-3-1
[0034] pK18-rrnB was transferred into Corynebacterium glutamicum MHZ-0513-3, and the recombinant was selected and exchanged on a selective medium containing 15 mg / L of kanamycin. The culture temperature was 33°C and the culture was inverted. The screened transformants were cultured overnight in a common liquid brain heart infusion medium at 33°C and shaken at 220 rpm on a rotary shaker. During this culture process, the transformants underwent a second recombination, and the vector sequence was removed from the genome by gene exchange. The culture was diluted in a continuous gradient (10 -2 Serial dilution up to 10 -4 ), the dilution was spread on a common solid brain heart infusion medium containing 10% sucrose and cultured at 33°C for 48 hours. The selected strains were further phenotypically verified, and the positive recombinants were amplified and sequenced using ID1-F / ID1-R to verify that the mutant strain obtained was the target strain and was named MHZ-0513-3-1.
[0035] The construction of plasmid pK18-A1T and strain MHZ-0513-3-2 was the same as above. The primers used were UP2-F, UP2-R, DN2-F, DN2-R, ID2-F, ID2-R, and Identification 2-F, respectively. Identification 2-F was used for mutation point identification. Using Identification 2-F / DN2-R as primers and exploring the appropriate annealing temperature, the correct transformants could be identified. For negative strains, no visible bands could be obtained.
[0036] The construction of plasmid pK18-ΔaceA and strain MHZ-0513-3-3 was the same as above, and the construction method was the same as above. The primers used were UP3-F, UP3-R, DN3-F, DN3-R, ID3-F, and ID3-R.
[0037] MHZ-0513-3-4 is a strain that includes both editing modes of "inserting the stop codon rrnB after aceA" and "replacing the start codon ATG with TTG", and the construction method is the same as above.
[0038] The strain MHZ-0513-3 was obtained by transformation of the model bacterium Corynebacterium glutamicum ATCC 14067 (disclosed in Chinese patent CN106701649A). The gene aceA is exactly the same. The plasmids pK18-rrnB and pK18-ATG were electroporated into ATCC 14067-glnA Y405F (Strain ATCC 14067-glnA Y405F The construction method was the same as above, and the primers used were UP4-F, UP4-R, DN4-F, DN4-R, identification 4-F, ID4-F, ID4-R, P82, and P85). The transformed strain was named 14067-glnA. Y405F -4.
[0039] The strains and corresponding genotypes obtained are shown below:
[0040] Table 2 Strains and corresponding genotypes
[0041]
[0042] Example 2
[0043] This example verifies the ability of the various recombinant strains constructed in Example 1 to produce glutamine through experiments. The specific process is as follows:
[0044] Fermentation verification method for glutamine production: The strain frozen in a -80°C glycerol tube was inoculated into the following slant culture medium for activation, and a bacterial moss was grown after culturing at 33°C for 24 hours. The bacterial moss was picked from the freshly activated slant and inoculated into the following seed culture medium, and cultured at 33°C, 100 rpm with shaking to the middle and late logarithmic growth stage for 5 hours to prepare a seed solution, and the seed solution was inoculated into a 500 ml shake flask containing 20 ml of fermentation medium at an inoculation rate of 10%, and cultured at 33°C, 150 rpm with shaking for 48 hours.
[0045] The results are shown in the following table (OD 562 The turbidity of the culture solution at 562 nm represents the cell mass, and Gln (g / L) represents the amount of accumulated L-glutamine).
[0046] The culture medium formula is as follows:
[0047] Slant culture medium: brain heart infusion 37g / L, agar 1.8%, sterilized at 121℃ 0.1MPa for 20min;
[0048] Seed culture medium: glucose 50 g / L, urea 5 g / L, KH2PO4 2.0 g / L, MgSO4·7H2O 1.0 g / L, corn steep liquor 30 g / L, pH 7.0;
[0049] Fermentation medium: glucose 90 g / L, (NH4)2SO4 40 g / L, KH2PO4 2.0 g / L, MgSO4·7H2O 1.0 g / L, corn steep liquor 10 g / L, CaCO3 50 g / L, pH 7.0.
[0050] Table 2 Detection of glutamine content in mutant strains
[0051] strains <![CDATA[OD 562 ]]> Gln(g / L) Acid production increase rate % MHZ-0513-3 43.3 28.9 -- MHZ-0513-3-1 44.2 31.8 10.0 MHZ-0513-3-2 43.9 32.1 11.1 MHZ-0513-3-3 42.1 29.5 2.0 MHZ-0513-3-4 43.6 33.8 17.0 14067 43.5 0.3 -- <![CDATA[14067-glnA Y405F ]]> 43.3 0.6 -- <![CDATA[14067-glnA Y405F -4]]> 42.9 0.72 20.0
[0052] As shown in Table 2, the terminator rrnB was inserted after aceA in MHZ-0513-3 to obtain strain MHZ-0513-3-1. The glutamine production in shake flask fermentation increased from 28.9 g / L to 31.8 g / L, and the acid production increased by 10.0%. It can be seen that the insertion of terminator rrnB after aceA significantly improved the glutamine production of the strain.
[0053] In MHZ-0513-3, the aceA start codon ATG was replaced with TTG to obtain strain MHZ-0513-3-2. The glutamine production in shake flask fermentation increased from 28.9 g / L to 32.1 g / L, and the acid production increased by 11.1%. It can be seen that the weakening of the aceA start codon significantly increased the glutamine production of the strain.
[0054] In MHZ-0513-3, 500bp of aceA gene was inactivated, and strain MHZ-0513-3-3 was obtained. The glutamine production in shake flask fermentation increased from 28.9g / L to 29.5g / L, and the acid production increased by 2.0%. The glutamine production increased, but the increase was small, significantly lower than the insertion of terminator rrnB and the weakening of the start codon. From this, it can be seen that the higher the degree of inactivation of the aceA gene, the better. Directly inactivating its 500bp gene will only increase the acid production capacity to a very limited extent.
[0055] MHZ-0513-3-4 includes both editing methods: inserting the terminator rrnB and replacing the start codon. The glutamine production in shake flask fermentation increased from 28.9g / L to 33.8g / L, and the acid production increased by 17%. This shows that inserting the terminator rrnB and weakening the start codon can play a synergistic role and is more conducive to the accumulation of glutamine.
[0056] In this example, the terminator and start codon attenuation inserted after aceA were confirmed to be effective in different strains. Y405F The fermentation results showed that the aceA post-insertion terminator and the weakened start codon were effective in different strains. Therefore, any one or both of the aceA post-insertion terminator and the weakened start codon were beneficial to the accumulation of glutamine. Obviously, other weakening methods, such as replacing the aceA start codon ATG with GTG, were beneficial to the accumulation of glutamine. Introducing this mutant into other glutamine-producing strains such as Enterobacter, Bacillus subtilis, Corynebacterium, etc. were beneficial to the accumulation of glutamine or its derivatives, such as arginine, tryptophan, etc.
[0057] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for improving the ability of a microorganism to produce glutamine or its derivatives, characterized in that: include: Reducing the expression level of isocitrate lyase in microorganisms.
2. The method according to claim 1, characterized in that By reducing the expression level of the isocitrate lyase encoding gene aceA, the expression level of isocitrate lyase in the microorganism is reduced; The method of reducing the expression level of the isocitrate lyase encoding gene aceA includes any one or more of the following methods: i) RNA interference technology; ii) replacement of promoter; iii) insertion of terminator; iv) replacement of start codon; v) knockout of large gene fragments; vi) gene mutation.
3. The method according to claim 2, characterized in that The expression level of the isocitrate lyase encoding gene aceA in the microorganism is reduced by replacing the start codon and / or inserting a terminator.
4. The method according to claim 3, characterized in that The replacement of the start codon is to replace the start codon with TTG; the insertion of the terminator is to insert the terminator rrnB after the gene encoding aceA of isocitrate lyase.
5. The method according to any one of claims 1 to 4, characterized in that: The isocitrate lyase comprises the amino acid sequence shown in SEQ ID NO.
1.
6. The method according to claim 5, characterized in that The gene encoding isocitrate lyase includes the nucleotide sequence shown as SEQ ID NO.
2.
7. The method according to any one of claims 1 to 6, characterized in that: The glutamine or its derivatives include one or more of glutamine, arginine or tryptophan.
8. The method according to any one of claims 1 to 6, characterized in that: The microorganisms include one or more of Enterobacter, Bacillus subtilis or Corynebacterium.
9. An aceA mutant, characterized in that The aceA mutant is encoded by the nucleotide sequence shown in SEQ ID NO.3 or SEQ ID NO.
4.
10. Use of the aceA mutant according to claim 9 or a biological material comprising the aceA mutant in improving the ability of a microorganism to produce glutamine or its derivatives.
